Table 3 PSC patients and controls enrolled in the current protocol (IRB #16-005892)
Variable | PSC patients | Controls |
|---|---|---|
n | 323 | 710 |
Age (yrs)a, median (IQR) | 52.6 (36.7–65.1) | 67.5 (58.3–73.3) |
Sex, n (%) male | 181 (56.0) | 226 (31.8) |
Raceb, n (%) Caucasian | 311 (96.3) | 693 (98.3) |
Available specimens, n (%) of participants [total # of aliquots] | ||
Genomic DNA / BC | 318 (98.5) [646] | 706 (99.4) [1,409] |
Plasma | 318 (98.5) [1,273] | 706 (99.4) [2,736] |
Serum | 316 (97.8) [1,143] | 705 (99.3) [2,432] |
PBMC | 317 (98.1) [967] | 706 (99.4) [2,118] |
RNA (whole blood) | 318 (98.5) [647] | 705 (99.3) [1,410] |
Cell-free DNA (plasma) | 315 (97.5) [321] | 703 (99.0) [703] |
Stool | 245 (75.8) [733] | 678 (95.5) [2,034] |
Urine | 269 (83.3) [1,224] | 676 (95.2) [3,131] |
Bile | 34 (10.5) [128] | na |
Liver tissue | 18 (5.6) [107] | na |
Age at PSC dx (yrs), median (IQR) | 41.5 (28.8–54.3) | na |
PSC duration (yrs)a, median (IQR) | 6.1 (2.1–12.6) | na |
IBD type, n (%) of patients | ||
Ulcerative colitis | 203 (62.8) | na |
Crohn’s Disease | 43 (13.3) | |
Indeterminate IBD | 6 (1.9) | |
No IBD | 71 (22.0) | |
Clinical follow-upc, n (%) of patients | ||
None | 103 (31.9) | na |
0–3 Years | 217 (67.2) | |
3–6 Years | 3 (0.9) | |
6 + Years | 0 | |
Liver transplant, n (%) of patients | ||
Prior to enrollment | 9 (2.8) | na |
In follow-up | 24 (7.4) | |
No liver transplant | 290 (89.8) | |
Advanced diseased, n (%) of patients | ||
Prior to enrollment | 87 (26.9) | na |
In follow-up | 20 (6.2) | |
No advanced disease | 216 (66.9) | |
Hepatobiliary Cancere, n (%) of patients | ||
Prior to enrollment | 22 (6.8) | na |
In follow-up | 7 (2.2) | |
No hepatobiliary cancer | 294 (91.0) | |